GlobeNewswire

Casa Systems Debuts New Axyom 5G Core

Dela

Superior network performance enables service providers to drive new revenue streams and reduce costs

 

ANDOVER, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Casa Systems (NASDAQ:CASA), a leading provider of end-to-end network infrastructure technology solutions for wireline and wireless networks today announced it will debut its 5G core at this year's Mobile World Congress. Designed to bring new levels of flexibility to mobile networks, Casa's 5G core delivers the performance and service creation capabilities that service providers need to realize potential new revenues and operational efficiencies from mobile core transformations.

Built on Casa's AxyomTM Ultra-Broadband Cloud, Casa's 5G Core was developed for the unique demands on mobile core software functions in edge computing and data center environments where those functions need to scale in multiple dimensions, be composed into an expanded range of 5G services, and be securely exposed to other functions.  The Axyom 5G Core architecture incorporates industry standards including a micro-service based architecture, as well as separation of control and user plans, but also leverages Casa's design innovations that dramatically improve performance, reduce resource requirements, and increase ease of operation. 

Casa's 5G core runs on standard servers in containers or virtual machines and is optimized for a distributed, virtual compute environment to deliver superior performance and surpass industry benchmarks:

  • Superior performance: Up to 5X greater throughput per vCPU when compared to competitors.  This performance will help service providers in their quest for both OPEX and CAPEX cost reductions.
  • Lean computing requirements:  An industry leading, minimal vCPU Virtual Network Function (VNF) footprint ensures efficient resource utilization and delivers high user-plane performance including at the edge of the network.
  • Simplified network evolution:  Casa's Axyom 5G core efficiently controls 4G devices as well, enabling the benefits of the 5G core architecture in 4G networks.
  • Differentiated Scaling:  Addition of a new scaling dimension with the support for both vertical and horizontal scaling. Vertical scaling delivers the ability to dynamically increase and decrease vCPUs within a single VNF that translates to more efficient and responsive use of compute resources.
  • Superior flexibility:  Casa's 5G Control and User Plane Separation (CUPS) solutions provides independent scaling and the ability to locate functions in a centralized data center or at the distributed network edge for Multi-access Edge Computing (MEC) applications.
  • Simplified service provisioning:  Up to 6X faster ability to bring up new services that allows service providers to rapidly respond to new market opportunities.

Casa's solution supports the 5G New Radio (NR) standard and key 5G Core capabilities including network slicing, service chaining, network programmability, and secure network exposure - all of which help service providers handle growing network traffic, monetize network capabilities and achieve greater service agility. 

At this week's Mobile World Congress in Barcelona, Casa Systems' will debut its Axyom 5G Core featuring demonstrations of its mobile core multi-dimensional scaling capabilities. Casa will also showcase other new solutions including a Cellular IoT Optimized Core, an Enhanced Small Cell Core, and new indoor and outdoor small cells.

"Casa has a clear vision for the future - a virtualized, converged and distributed network.  We are reimagining the network infrastructure to deliver high performance and operational efficiency in the 5G era," said Jerry Guo, CEO of Casa Systems. "Our Axyom solutions deliver on key dimensions including Gbps per vCPU, and our 5G Core gives service providers the performance, flexibility, and economics they need to capitalize on growing demand and new use cases."

About Casa Systems, Inc.
Casa Systems, Inc. (NASDAQ:CASA) delivers software solutions that enable wireless and wireline broadband providers to meet the growing demand for gigabit bandwidth and services. We provide a suite of distributed and virtualized solutions for fixed and mobile 5G ultra-broadband networks. Our solutions are commercially deployed in over 70 countries serving more than 400 customers, including regional service providers as well as some of the world's largest Tier 1 broadband service providers.

To arrange a briefing or product demonstration, please contact us at sales@casa-systems.com or visit our website at http://www.casa-systems.com.

CONTACT INFORMATION:
Alicia Thomas 
Casa Systems, Inc.   
100 Old River Road
Andover, Mass. 01810  
+1.817.909.8921   
Alicia.thomas@casa-systems.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Casa Systems, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum